Pricing Log in Create free account
Friday 6 November 2026 Export ABCL’s income statement to Excel — free account

AbCellera Biologics Inc.

ABCL Healthcare Biotechnology

AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.

Revenue
−76.3%
EPS
−50.0%
Free cash flow
+152.0%

Quarter to June 2026, against a year earlier

11.89 0.76 +6.83%
Market cap
$3.6B
P/E
0.0×
Fwd P/E
−18.4×
Dividend yield
—
F-score
5/9
Altman Z
1.66
Beneish M
−1.06
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

AbCellera Biologics Inc. (ABCL) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, AbCellera Biologics Inc. (ABCL) trades at a EV/Sales of 46.4×. Over the past ten years it has ranged from −2.3× (April 2025) to 59.9× (September 2026); the current reading is higher than 98% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.2× (16.86%)
FY2024 7.5× (67.56%)
FY2023 23.0× 521.40%
FY2022 3.7× (56.58%)
FY2021 8.5× (65.82%)
FY2020 24.9× —
FY2019 0.0× —
FY2018 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 27.8× 313.74%
Mar 2026 6.7× 8.13%
Dec 2025 6.2× (77.77%)
Sep 2025 27.9× 104.29%
22 more quarters

Against its own ten years

Low −2.3× High 59.9×
Ten-year median 7.8×
Current reading's percentile 97

EV/Sales against peers

Company EV/Sales
PBLS Parabilis Medicines, Inc. compare n/m
EWTX Edgewise Therapeutics, Inc. compare n/m
ACAD ACADIA Pharmaceuticals Inc. compare 2.2×
ARQT Arcutis Biotherapeutics, Inc. compare 6.7×
IOVA Iovance Biotherapeutics, Inc. compare 8.5×
TNGX Tango Therapeutics, Inc. compare 34.7×
ABCL AbCellera Biologics Inc. 43.5×
XENE Xenon Pharmaceuticals Inc. compare 169×
RLAY Relay Therapeutics, Inc. compare 231×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ABCL